Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

CytoMed Therapeutics (GDTC) CytoMed Therapeutics (GDCT, or the Company), a Singapore-based biotechnology company trading on the NASDAQ, is developing multiple gamma delta chimeric antigen receptor ...

SINGAPORE, July 6, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary ...

GDTC is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of GDTC shares has decreased $0.04 since the market last closed. This is a 3.87% ...